# Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)

> **NCT02065401** · PHASE1 · WITHDRAWN · sponsor: **Shire**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Deferitazole (disodium salt, granule)
- **DRUG:** Deferitazole (disodium salt, tablet)
- **DRUG:** Deferitazole (magnesium hydroxide salt)

## Key facts

- **NCT ID:** NCT02065401
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-02-28
- **Primary completion:** 2014-03-19
- **Final completion:** 2014-03-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was withdrawn until the evaluation of the nonclinical rat findings is complete.
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02065401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02065401, "Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02065401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*